OptiBiotix Health plc (LON:OPTI) presented at the 2nd Microbiome R&D and Business Collaboration Congress: Asia, part of Global Engage’s worldwide microbiome series. The conference was attended by over 180 leading industry and academics involved in research and development into the Microbiome from around the world, including delegates from most of the major corporates in this field. OptiBiotix’ CEO, Stephen OHara presented on the companies proprietary Optiscreen® and Optibiotix® technology platforms which create novel compounds to modulate the human microbiome. The Optiscreen® platform had been used to create a novel supplement which clinical studies have demonstrated large reductions in serum cholesterol and clinically significant reductions in blood pressure. The company announced for the first time a new class of product, an OptiBiotic®, which they defined as a combination of a targeted probiotic and prebiotic in which the prebiotic selectively enhances the in vivo growth of the probiotic and accentuates its functional properties. They felt this approach signalled the beginning of next generation products which will lead to the adoption of human microbiome treatments into mainstream healthcare.
OptiBiotix Health Plc CEO, Stephen OHara said ‘ This conference brings together leading scientific and business leaders from around the world increasing the global awareness of OptiBiotix’s technologies and its product pipeline. We are delighted that our presentation attracted so much scientific and commercial interest and anticipate this will lead to a number of new partnering opportunities’
